Welcome to our dedicated page for ISR news (Ticker: isr), a resource for investors and traders seeking the latest updates and insights on ISR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ISR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ISR's position in the market.
Isoray, a medical technology company specializing in seed brachytherapy, announced that CEO Lori Woods will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23 at 1:40 p.m. ET. Together with CFO Jonathan Hunt, they will conduct virtual meetings with institutional investors. A live webcast of the presentation will be available on Isoray's website and an on-demand replay will be offered for 90 days following the event.
Isoray is the sole producer of Cesium-131 brachytherapy seeds, enhancing treatment options for various conditions.
Isoray, Inc. (ISR) has scheduled a conference call for September 17, 2020, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year ending June 30, 2020. The company is noted for being the sole producer of Cesium-131 brachytherapy seeds, enhancing treatment options in brachytherapy. A press release detailing the financial results will be issued after the market closes on the same day. Investors can participate via phone or a live webcast at this link.
Isoray, Inc. (NYSE AMERICAN: ISR) will host a conference call on September 17, 2020, at 4:30 p.m. Eastern Time to discuss its financial results for the fourth quarter and fiscal year ending June 30, 2020. The company will issue a press release with these results after the U.S. markets close that day. Interested parties can listen via phone or access a webcast. Isoray is the sole producer of Cesium-131 brachytherapy seeds, which provide innovative treatment options.
Isoray has entered into a research grant agreement with the University of Cincinnati Physicians Company to study the treatment of recurrent head and neck cancers. The trial will focus on the safety and effectiveness of combining pembrolizumab (Keytruda) with Cesium-131 brachytherapy post-surgery. Fifty patients with recurrent cancers will be enrolled. The study aims to explore potential synergies between traditional therapies and immunotherapy. CEO Lori Woods emphasized the importance of this trial in advancing treatment options for hard-to-treat cancers.
Isoray announced positive results from a ten-year study on Cesium-131 internal radiation therapy for prostate cancer. The University of Pittsburgh study showed a 95.3% success rate for low-risk patients, 90.1% for intermediate-risk, and 56.6% for high-risk patients. The therapy's advantages include reduced urinary morbidity and faster recovery times, as noted by study lead Dr. Ronald Benoit. CEO Lori Woods highlighted that these findings mark a significant milestone with over 1,000 patients treated, confirming Cesium-131's effectiveness in localized prostate cancer treatment.
Isoray, Inc. (NYSE AMERICAN: ISR) reported its financial results for Q3 fiscal 2020, with revenue increasing by 50% to $2.88 million, driven by a 42% rise in prostate brachytherapy revenue. Gross profit margin improved to 59.2%, up from 45.7% last year. However, the company faced a 20% drop in preliminary sales for April due to COVID-19 related procedure cancellations. For the first nine months, revenue grew 37% to $7.40 million, and net losses narrowed significantly. Cash and equivalents stood at $2.41 million, with no debt and shareholders’ equity at $5.82 million.
Isoray, Inc. (NYSE American: ISR) announced approval from the Centers for Medicare and Medicaid Services (CMS) for 64 ICD-10-PCS billing codes for Cesium-131 reimbursement in hospital inpatient settings. Effective October 1, 2020, these codes facilitate billing for surgical procedures utilizing Cesium-131, aimed at treating hard-to-treat cancers, including lung and brain cancers. CEO Lori Woods emphasized that this approval promotes patient access to treatment and fair reimbursement for hospitals. Isoray is the only supplier of Cesium-131, a high-energy isotope used in brachytherapy, providing targeted cancer treatment with minimal radiation exposure.
Summary not available.